SettledBusiness
OpenAI acquires Orchestra Bio to build AI agents for drug development
OpenAI announced Oct. 20 that it acquired Orchestra Bio, a four-year-old startup whose AI agents handle drug discovery operations such as finances and clinical trial scheduling, per TechCrunch. The team will work on Rosalind, OpenAI's life sciences model, and Rosalind Workbench. Terms were not disclosed.
- HEAT
- OUTLETS
- 16
- FIRST SEEN
- LAST SIGNAL
Primary source
TechCrunchtechcrunch.com/2026/10/20/openai-acquires-startup-orchestra-bio%E2%81%A0-to-beef-up-its-biotech-business/Coverage · 18 articles, oldest first
Tuesday, October 20, 2026
OpenAIPrimary
openai.com/index/openai-to-acquire-orchestra-bio/
Wednesday, October 21, 2026